医疗大数据在恶性肿瘤诊治中的应用

摘要/Abstract

摘要：随着信息技术的发展和大数据技术的广泛运用，传统的肿瘤诊疗方式已经不能满足医学的需要。医疗大数据的应用深刻地改变了肿瘤诊疗模式，同时也使人们对恶性肿瘤本质有了更深入的认识。医疗大数据统计分析以及管理技术正推动恶性肿瘤诊治从“个体化治疗”时代进入“精准医疗”时代，这使得恶性肿瘤的预测、诊断、治疗以及监测等方面正在发生巨大的变革，同时也面临着各种难题和挑战。

关键词:肿瘤,基因组学,治疗应用,大数据,靶向治疗

Abstract:With the extensive use of information technology and the development of big data technology, the traditional treatment methods for cancer are not meeting our needs. The application of medical large data has now changed our tumor treatment model profoundly, but also brings a deeply cognition to the nature of malignant tumor. Development of medical big data analysis and management technologies are driving malignancy treatment model from "individual treatment" era into the "precision medicine" era, which allows us to change the prediction, diagnosis, treatment and monitor of malignancy. There are also a variety of challenges to resolve.

Key words:Neoplasms,Genomics,Therapeutic uses,Big data,Targeted therapy

周殷杰,向明飞,李涛. 医疗大数据在恶性肿瘤诊治中的应用[J]. 国际肿瘤学杂志, 2016, 43(1): 75-78.

Zhou Yinjie, Xiang Mingfei, Li Tao. Application of big medical data in cancer diagnosis and treatment[J]. Journal of International Oncology, 2016, 43(1): 75-78.

参考文献

［1］ Schilsky RL, Michels DL, Kearbey AH, et al. Building a rapid learning health care system for oncology: the regulatory framework of CancerLinQ［J］. J Clin Oncol, 2014, 32(22): 2373-2379. DOI:10.1200/JCO.2014.56.2124. ［2］Helft M. Can big data cure cancer?［J］. Fortune, 2014, 170(2): 7074, 76, 78. ［3］Tomczak K, Czerwińska P, Wiznerowicz M. The cancer genome atlas (TCGA): an immeasurable source of knowledge［J］. Contemp Oncol (Pozn), 2015, 19(1A): A68-A77. DOI:10.5114/wo.2014.47136. ［4］Wilks C, Cline MS, Weiler E, et al. The cancer genomics hub (CGHub): overcoming cancer through the power of torrential data［J］. Database (Oxford), 2014, 2014: pii: bau093. DOI:10.1093/database/bau093. ［5］International Cancer Genome Consortium, Hudson TJ, Anderson W, et al. International network of cancer genome projects［J］. Nature, 2010, 464(7291): 993-998. DOI:10.1038/nature08987. ［6］Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes［J］. Science, 2013, 339(6127): 1546-1558. DOI:10.1126/science.1235122. ［7］Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene［J］. Science, 2009, 324(5924): 217. DOI:10.1126/science.1171202. ［8］Thirumurthi U, Shen J, Xia W, et al. MDM2mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer［J］. Sci Signal, 2014, 7(336): ra71. DOI:10.1126/scisignal.2005076. ［9］Taylor CR. From microscopy to whole slide digital images: a century and a half of image analysis［J］. Appl Immunohistochem Mol Morphol, 2011, 19(6): 491-493. DOI:10.1097/PAI.0b013e318229ffd6. ［10］ Gu J, Taylor CR. Practicing pathology in the era of big data and personalized medicine［J］. Appl Immunohistochem Mol Morphol, 2014, 22(1): 1-9. DOI:10.1097/PAI.0000000000000022. ［11］ Muzny DM, Bainbridge MN, Chang K, et al. Comprehensive molecular characterization of human colon and rectal cancer［J］. Nature, 2012, 487(747): 330-337. DOI:10.1038/nature11252. ［12］ Kunz M. Genomic signatures for individualized treatment of malignant tumors［J］. Curr Drug Discov Technol, 2008, 5(1): 9-14. ［13］ Greene CS, Tan J, Ung M, et al. Big data bioinformatics［J］. J Cell Physiol, 2014, 229(12): 1896-1900. DOI:10.1002/jcp.24662. ［14］ Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated datamining platform［J］. Neoplasia, 2004, 6(1): 1-6. ［15］ Dou XL, Bai CM. Cancer biomarkers and personalized cancer medicine［J］. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2015, 37(1): 113-117. DOI:10.3881/j.issn.1000-503X.2015.01.021. ［16］ Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma［J］. N Engl J Med, 2009, 361(10): 947-957. ［17］ Incorvati JA, Shah S, Mu Y, et al. Targeted therapy for HER2 positive breast cancer［J］. J Hematol Oncol, 2013, 6(1): 23731980. DOI:10.1186/1756-8722-6-38. ［18］ Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer［J］. Clin Chem, 2015, 61(1): 112-123. DOI:10.1373/clinchem.2014.222679. ［19］ Cappelletti V, Appierto V, Tiberio P, et al. Circulating biomarkers for prediction of treatment response［J］. J Natl Cancer Inst Monogr, 2015 (51): 60-63. DOI:10.1093/jncimonographs/lgv006. ［20］ Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early and latestage human malignancies［J］. Sci Transl Med, 2014, 6(224): 224ra24. DOI:10.1126/scitranslmed.3007094. ［21］ Kim K. Big data key to improving health care［R］. AAMC Reporter, 2014, January. ［22］ Taitsman JK, Grimm CM, Agrawal S. Protecting patient privacy and data security［J］. N Engl J Med, 2013, 368(11): 977-979. DOI:10.1056/NEJMp1215258. ［23］李丹丹. 论个人医疗信息的法律保护［J］. 吉首大学学报: 社会科学版, 2015, 2(2): 87-93. DOI:10.13438/j.cnki.jdxb.2015.02.014. ［24］ Huang J, Yu Y. Bioinformatics of tumor molecular targets from big data［J］. Zhonghua Wei Chang Wai Ke Za Zhi, 2015, 18(1): 9-12. ［25］ Alyass A, Turcotte M, Meyre D. From big data analysis to personalized medicine for all: challenges and opportunities［J］. BMC Med Genomics, 2015, 8(1): 33. DOI:10.1186/s12920-015-0108-y.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.